Zobrazeno 1 - 10
of 362
pro vyhledávání: '"Feng-hua WANG"'
Autor:
Feng‐Hua Wang, Xiao‐Tian Zhang, Lei Tang, Qi Wu, Mu‐Yan Cai, Yuan‐Fang Li, Xiu‐Juan Qu, Hong Qiu, Yu‐Jing Zhang, Jie‐Er Ying, Jun Zhang, Ling‐Yu Sun, Rong‐Bo Lin, Chang Wang, Hao Liu, Miao‐Zhen Qiu, Wen‐Long Guan, Sheng‐Xiang Rao, Jia‐Fu Ji, Yan Xin, Wei‐Qi Sheng, Hui‐Mian Xu, Zhi‐Wei Zhou, Ai‐Ping Zhou, Jing Jin, Xiang‐Lin Yuan, Feng Bi, Tian‐Shu Liu, Han Liang, Yan‐Qiao Zhang, Guo‐Xin Li, Jun Liang, Bao‐Rui Liu, Lin Shen, Jin Li, Rui‐Hua Xu
Publikováno v:
Cancer Communications, Vol 44, Iss 1, Pp 127-172 (2024)
Abstract The 2023 update of the Chinese Society of Clinical Oncology (CSCO) Clinical Guidelines for Gastric Cancer focuses on standardizing cancer diagnosis and treatment in China, reflecting the latest advancements in evidence‐based medicine, heal
Externí odkaz:
https://doaj.org/article/ddb71d41f751472a92fb64e883303e66
Autor:
De-Shen Wang, Chao Ren, Shan-Shan Li, William Pat Fong, Xiao-Jun Wu, Jian Xiao, Bin-Kui Li, Yun Zheng, Pei-Rong Ding, Gong Chen, Miao-Zhen Qiu, Zhi-Qiang Wang, Feng-Hua Wang, Hui-Yan Luo, Feng Wang, Xiao-Zhong Wang, Ling-Yun Wang, De-Jin Xie, Tao Chen, Li-Ren Li, Zhen-Hai Lu, Xiao-Hui Zhai, Tian-Shu Liu, Ying Yuan, Jia-Qi Chen, Qiong Tan, Zhi-Zhong Pan, De-Sen Wan, Rong Zhang, Yun-Fei Yuan, Rui-Hua Xu, Yu-Hong Li
Publikováno v:
PLoS Medicine, Vol 21, Iss 5, p e1004389 (2024)
BackgroundIt remains unclear whether intensification of the chemotherapy backbone in tandem with an anti-EGFR can confer superior clinical outcomes in a cohort of RAS/BRAF wild-type colorectal cancer (CRC) patients with initially unresectable colorec
Externí odkaz:
https://doaj.org/article/b9e6a45661f549378ef2d8ab851edf5e
Autor:
Liang-Jun Qin, Hui Xu, Li-Ping Li, Shu-Hua Li, Shuo-Yu Xu, Kai Chen, Tianyou Yang, Feng-Hua Wang, Liandong Zuo, Liang Zeng, Hai-Yun Wang
Publikováno v:
Heliyon, Vol 10, Iss 9, Pp e30901- (2024)
Recent advances have revealed that the role of the immune system is prominent in the antitumor response. In the present study, it is aimed to provide an expression profile of tumor-infiltrating lymphocytes (TILs), including mature B cells, plasma cel
Externí odkaz:
https://doaj.org/article/b2a74547e1f34dac97560d34b9711edb
Autor:
Renjing Zhang, Yang Yang, Chunfang Hu, Mayan Huang, Wenjian Cen, Dongyi Ling, Yakang Long, Xin-Hua Yang, Boheng Xu, Junling Peng, Sujie Wang, Weijie Zhu, Mingbiao Wei, Jiaojiao Yang, Yuxia Xu, Xu Zhang, Jiangjun Ma, Fang Wang, Hongtu Zhang, Peiqing Ma, Xiaojun Zhu, Guohui Song, Li-Yue Sun, De-Shen Wang, Feng-Hua Wang, Yu-Hong Li, Sandro Santagata, Qin Li, Yan-Fen Feng, Ziming Du
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-15 (2023)
Abstract Solitary fibrous tumors (SFTs) are rare mesenchymal tumors with unpredictable evolution and with a recurrence or metastasis rate of 10-40%. Current medical treatments for relapsed SFTs remain ineffective. Here, we identify potential therapeu
Externí odkaz:
https://doaj.org/article/40b85ffd685f4b10bbdd4c6df9fa3b0a
Autor:
Miao-Zhen Qiu, Chaoye Wang, Zhiying Wu, Qi Zhao, Zhibin Zhao, Chun-Yu Huang, Wenwei Wu, Li-Qiong Yang, Zhi-Wei Zhou, Yu Zheng, Hong-Ming Pan, Zexian Liu, Zhao-Lei Zeng, Hui-Yan Luo, Feng Wang, Feng-Hua Wang, Si-Yu Yang, Meng-Xing Huang, Zhexiong Lian, Haiyan Zhang, Rui-Hua Xu
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 8, Iss 1, Pp 1-13 (2023)
Abstract Epstein‒Barr virus (EBV)-associated gastric cancer (GC) manifests an intriguing immunotherapy response. However, the cellular basis for EBV-imprinted tumour immunity and on-treatment response remains undefined. This study aimed to finely c
Externí odkaz:
https://doaj.org/article/070815274a0c48edad394ffc82fe221e
Autor:
Chunmei Wang, Haibo Wang, Feng-Hua Wang, Li Jiang, Meiping Wang, Ya-chan Ning, Li-po Song, Pei-juan Li, Meng-xi Ding, Qian-Qian Pei, Shi-min Hu
Publikováno v:
BMJ Open, Vol 13, Iss 10 (2023)
Introduction Whether and when to monitor the amount of anti-factor Xa (aFXa) activity in critically ill patients with complex diseases to prevent venous thromboembolism (VTE) remain unclear. This study is a randomised controlled trial to investigate
Externí odkaz:
https://doaj.org/article/2da708dd44d94dcf8b7798d44596dcee
Autor:
Jiaojiao Yang, Liyue Sun, Xiao‐Yun Liu, Chan Huang, Junling Peng, Xinxin Zeng, Hailin Zheng, Wenjian Cen, Yu‐Xia Xu, Weijie Zhu, Xiao‐Yan Wu, Dongyi Ling, Lu‐Lu Zhang, Mingbiao Wei, Ye Liu, Deshen Wang, Feng‐Hua Wang, Yu‐Hong Li, Qin Li, Ziming Du
Publikováno v:
Clinical and Translational Medicine, Vol 13, Iss 9, Pp n/a-n/a (2023)
Abstract Background Cysteine dioxygenase 1 (CDO1) is frequently methylated, and its expression is decreased in many human cancers including breast cancer (BC). However, the functional and mechanistic aspects of CDO1 inactivation in BC are poorly unde
Externí odkaz:
https://doaj.org/article/7f471a52d3d5403ca1457cb6293d5abd
Autor:
Xiao-Li Wei, Fu-Rong Liu, Ji-Hong Liu, Hong-Yun Zhao, Yang Zhang, Zhi-Qiang Wang, Miao-Zhen Qiu, Fei Xu, Qiu-Qiong Yu, Yi-Wu Du, Yan-Xia Shi, De-Sheng Wang, Feng-Hua Wang, Rui-Hua Xu
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-10 (2022)
PIK3CA is a commonly mutated cancer-associated gene, making it an attractive therapeutic target. Here, the authors report the results of a first-in-human phase Ia trial to assess the safety and recommended phase II dose of CYH33, a PI3Kα inhibitor,
Externí odkaz:
https://doaj.org/article/e1f16c3559294902ac1b66c1f48464a7
Autor:
Ming-Yu Lai, Shi-Yang Kang, Yu-Ting Sun, Ting-Ting Quan, Shi-Xun Lu, Cai-Yun He, Zhi-Wei Zhou, Li-Qiong Yang, Hui-Yan Luo, Feng-Hua Wang, Yu-Hong Li, Rui-Hua Xu, Wen-Long Guan, Miao-Zhen Qiu
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Both Response Evaluation Criteria in Solid Tumors (RECIST) and tumor regression grade (TRG) play key roles in evaluating tumor response. We analyzed the consistency of TRG and RECIST 1.1 for gastric cancer (GC) patients and compar
Externí odkaz:
https://doaj.org/article/a6bf45d872e24b9d9ef7cded62b68d32
Autor:
Miao-Zhen Qiu, Qingjian Chen, Dan-Yang Zheng, Qi Zhao, Qi-Nian Wu, Zhi-Wei Zhou, Li-Qiong Yang, Qiu-Yun Luo, Yu-Ting Sun, Ming-Yu Lai, Sha-Sha Yuan, Feng-Hua Wang, Hui-Yan Luo, Feng Wang, Yu-Hong Li, Hui-Zhong Zhang, Rui-Hua Xu
Publikováno v:
Cell Reports, Vol 42, Iss 6, Pp 112576- (2023)
Summary: Gastric mixed adenoneuroendocrine carcinoma (MANEC) is a clinically aggressive and heterogeneous tumor composed of adenocarcinoma (ACA) and neuroendocrine carcinoma (NEC). The genomic properties and evolutionary clonal origins of MANEC remai
Externí odkaz:
https://doaj.org/article/bf5aeca0e50d4f5bb3972a430c761164